Drug · CHEMBL137
METRONIDAZOLE
7 sourcespipelines-2026-09-18-0.3.1
Cite this record
ConductScience Library. METRONIDAZOLE. Drugs and targets, record CHEMBL137. Release pipelines-2026-09-18-0.3.1, 18 Sept 2026. https://conductscience.org/library/drugs/CHEMBL137
On this page
Drug
Names and IDs as ChEMBL gives them, through Open Targets.
- Brand names
Acea, Anabact, Drazifon, Elyzol, Flagyl, Flagyl 375, Flagyl compak, Flagyl er, Flagyl-400, Flagyl-s, Likmez, Metric 21, Metro i.v., Metro iv, Metrocream, Metrogel, Metrogel-vaginal, Metrolotion, Metrolyl, Metromidol, Metronidazole component of helidac, Metronidazole component of pylera, Metrosa, Metrotop, Neutratop, Noritate, Norzol, Nuvessa, Protostat, Rosiced, Rozex, Satric, Vaginyl, Vandazole, Zadstat, Zidoval, Zyomet
- ChEMBL
- Other names
- BAY-5360, BAYER 5360, BAYER-5360, Deflamon, Gineflavir, Likmez, Metronidazol, NSC-50364, NSC-69587, Orvagil, RP 8823, RP-8823
- ChEMBL
- Open Targets' highest stage
- Approval, for 13 of its 91 diseases, from ATC, DailyMed, PMDA and TTD
- Open Targets
Targets0
The targets ChEMBL's mechanism records give for the drug, through Open Targets. A mechanism record says what the drug acts on, not how strongly.
None in this release.
Diseases91
The diseases Open Targets' clinical reports study the drug for, the most trial reports first. The stage is Open Targets', the highest any of its sources reports for the pair, and each row names the sources that report it.
1 to 10 of 91Source Open Targets
See all 91 diseasesTrials518
Trials whose record names the drug by a name ChEMBL states, posted results first, then the largest. Open Targets read each trial's text to find its drugs. 4 more that Open Targets linked to it are not shown, since the release's checks do not confirm them.
| Trial | Title | Phase | Participants | Results first posted | Named as | Linked by | Source |
|---|---|---|---|---|---|---|---|
| NCT02800785 | The Comparison of Outcomes of Antibiotic Drugs and Appendectomy (CODA) Trial | 1,552 | 2023-04-18 | metronidazole | Its name | ClinicalTrials.gov | |
| NCT00667368 | Bacterial Vaginosis Home Screening to Prevent STDs | Phase 3 | 1,370 | 2015-10-29 | metronidazole | Its name | ClinicalTrials.gov |
| NCT01493947 | CD5024 1% [Ivermectin 1%] Cream Versus Metronidazole 0.75% Cream in Papulopustular Rosacea (PPR) Study | Phase 3 | 962 | 2015-10-28 | metronidazole | Its name | ClinicalTrials.gov |
| NCT01832480 | Trichomonas Vaginalis Repeat Infections Among HIV Negative Women | Phase 3 | 623 | 2019-02-12 | metronidazole | Its name | ClinicalTrials.gov |
| NCT01254344 | Efficacy and Safety of Ertapenem Sodium (MK-0826) Following Colorectal Surgery in Chinese Adults (MK-0826-056) | Phase 3 | 599 | 2012-11-16 | metronidazole | Its name | ClinicalTrials.gov |
| NCT00334633 | Treatment of Bacterial Vaginosis (BV) With Tinidazole | Phase 4 | 593 | 2011-06-23 | metronidazole | Its name | ClinicalTrials.gov |
| NCT01445678 | Study Comparing the Safety and Efficacy of Intravenous CXA-201 and Intravenous Meropenem in Complicated Intraabdominal Infections | Phase 3 | 494 | 2015-01-15 | metronidazole | Its name | ClinicalTrials.gov |
| NCT01499290 | Compare Ceftazidime-Avibactam + Metronidazole Versus Meropenem for Hospitalized Adults With Complicated Intra-Abdominal Infections | Phase 3 | 493 | 2016-03-01 | metronidazole | Its name | ClinicalTrials.gov |
| NCT01726023 | Compare Ceftazidime-Avibactam + Metronidazole vs Meropenem for Hospitalized Adults With Complicated Intra-Abd Infections | Phase 3 | 486 | 2016-04-14 | metronidazole | Its name | ClinicalTrials.gov |
| NCT02308007 | Multi-Center Study of New Medications to Treat Vaginal Infections | Phase 3 | 475 | 2020-08-04 | metronidazole, terconazole/metronidazole | Its name | ClinicalTrials.gov |
1 to 10 of 518
See all 518 trialsComparisons in its trials143
Comparisons Trial comparisons calculated in the trials whose record names the drug, most participants first. A comparison in one of its trials does not always compare the drug, so read the two groups.
| Comparison | Group 1, with the outcome | Group 2, with the outcome | Participants | Trial | Source |
|---|---|---|---|---|---|
| Antibiotics Therapy Arm vs Appendectomy Arm: Rates of Participants With Appendiceal Cancer | 4 of 776 | 6 of 776 | 1,552 | NCT02800785 | Trial comparisons |
| Intervention vs Control: serious adverse events | 7 of 683 | 3 of 682 | 1,365 | NCT00667368 | Trial comparisons |
| Antibiotics Therapy Arm vs Appendectomy Arm: Total Number of Patients Who Had Resolution of Appendicitis Symptoms at 30 Days | 462 of 676 | 466 of 663 | 1,339 | NCT02800785 | Trial comparisons |
| Antibiotics Therapy Arm vs Appendectomy Arm: Number of Participants With at Least One Complications From Treatment | 37 of 676 | 21 of 656 | 1,332 | NCT02800785 | Trial comparisons |
| Antibiotics Therapy Arm vs Appendectomy Arm: deaths from any cause | 0 of 676 | 0 of 656 | 1,332 | NCT02800785 | Trial comparisons |
| Antibiotics Therapy Arm vs Appendectomy Arm: serious adverse events | 19 of 676 | 19 of 656 | 1,332 | NCT02800785 | Trial comparisons |
| CAZ-AVI + Metronidazole vs Meropenem: serious adverse events | 17 of 529 | 15 of 529 | 1,058 | NCT01499290 | Trial comparisons |
| CXA-201 and Metronidazole as Treatment for cIAI vs Meropenem as Treatment for cIAI: serious adverse events | 39 of 482 | 36 of 497 | 979 | NCT01445678 | Trial comparisons |
| Antibiotics Therapy Arm vs Appendectomy Arm: Rate of Participants With Perforated Appendicitis | 59 of 185 | 99 of 621 | 806 | NCT02800785 | Trial comparisons |
Trichomonas (TV) Positive After 2 g Dose vs Trichomonas (TV) Positive After Metronidazole (MTZ) Multi Dose: Number of Subjects That Were Trichomonas Vaginalis (TV) Positive After Treatment With Metronidazole (MTZ) | 58 of 311 | 34 of 312 | 623 | NCT01832480 | Trial comparisons |
1 to 10 of 143
See all 143 comparisons in its trialsPapers from its trials353
The papers the trials whose record names the drug list on ClinicalTrials.gov as their results (RESULT) or as drawn from them (DERIVED), results first, newest first.
Tests in its trials0
The tests ConductCognition runs that the trials whose record names the drug name in their registered outcomes, as ScienceGraph matched them. ConductCognition's list names the tests it runs, not every test a trial used.
None in this release.
Data dates
The date of each source this release read.
Sources 7
- ClinicalTrials.gov's posted results, through CTTI's AACTFreely available. Acknowledgement requested
- ChEMBL, through Open TargetsCC BY-SA 3.0
- ConductCognition's list of its testsOur own data
- ClinicalTrials.govNo license stated
- NLM's MeSHNLM's terms
- Open TargetsCC0 1.0
- PubMedNLM's terms
Each source's terms
- ClinicalTrials.gov's posted results, through CTTI's AACTClinicalTrials.gov data via Aggregate Analysis of ClinicalTrials.gov (AACT), CTTI. CTTI makes its materials freely available and requests acknowledgement. https://aact.ctti-clinicaltrials.org/documentation/299
- ChEMBL, through Open TargetsCC BY-SA 3.0, for the parts from ChEMBL. Read on 8 Nov 2026 at https://platform-docs.opentargets.org/licence
- ConductCognition's list of its testsOur own data: ConductCognition's list of its tests, https://conductcognition.com
- ClinicalTrials.govnone stated
- NLM's MeSHNLM's
- Open TargetsCC0 1.0. Open Targets asks that users cite its latest paper: Buniello et al. 2025, Open Targets Platform: facilitating therapeutic hypotheses building in drug discovery, Nucleic Acids Research 53(D1):D1467, PMID 39657122. Read on 8 Nov 2026 at https://platform-docs.opentargets.org/licence
- PubMedNLM's terms
ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions.
For software
Read this drug from software.
The record and each of its lists are JSON, twenty rows a page. No key.
GET https://conductscience.org/api/drugs/v1/CHEMBL137
GET https://conductscience.org/api/drugs/v1/CHEMBL137/diseases?page=2